# Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

> **NCT05741346** · PHASE2 · TERMINATED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** BCX9930

## Key facts

- **NCT ID:** NCT05741346
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-18
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741346, "Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05741346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*